AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “overweight” rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Monday, MarketBeat reports.
Other analysts have also issued research reports about the company. Jefferies Financial Group increased their price objective on AstraZeneca from GBX 71 ($0.94) to GBX 74 ($0.98) and gave the company a “hold” rating in a report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 ($145.31) price target on shares of AstraZeneca in a research note on Tuesday, September 3rd. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, July 25th. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, May 28th. Finally, Berenberg Bank reiterated a “buy” rating and issued a £150 ($198.15) target price on shares of AstraZeneca in a research note on Monday, September 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of £105.53 ($139.41).
Check Out Our Latest Stock Report on AstraZeneca
AstraZeneca Stock Down 0.4 %
Insider Activity at AstraZeneca
In related news, insider Michel Demare bought 2,000 shares of the stock in a transaction dated Friday, September 13th. The shares were purchased at an average price of GBX 118 ($1.56) per share, for a total transaction of £2,360 ($3,117.57). 0.04% of the stock is currently owned by insiders.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
- Five stocks we like better than AstraZeneca
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What is the NASDAQ Stock Exchange?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.